This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Awad, A. G. Articles by Voruganti, L. N.P. Search for Related Content PubMed PubMed Citation Articles by Awad, A. G. Articles by Voruganti, L. N.P. Social Bookmarking                         What's this?

Quality of Life and New Antipsychotics in Schizophrenia Are Patients Better Off?

Department of Psychiatry, University of Toronto & Humber River Regional Hospital, 2175 Keele Street, Toronto, Ontario M6M 3Z4, Canada

Lakshmi N.P. Voruganti

Department of Psychiatry, University of Western Ontario, Victoria Hospital, London Health Sciences Centre, 392 South Street, London, Ontario N6A 4G5, Canada

The recent introduction of several antipsychotic medications has raised expectations for better pharmacological management of schizophrenia. Although conventional and new neuroleptics (Risperidone, Olanzapine, Seroquel and soon to be released Ziprasidone) are generally comparable in terms of efficacy; the new antipsychotic medications possess a better side-effects profile and are overall, much better tolerated. The reintroduction of Clozapine as an effective antipsychotic for treatment refractoriness has also improved management for a segment of the schizophrenic population who failed to respond adequately to other antipsychotic medications. Such increased benefits from new antipsychotic medications come with a higher acquisition cost that has somewhat strained the historically low psychiatric budgets. The question then was whether the expected benefits of the new antipsychotics can offset the high cost of these medications in the long-term. In that context, quality of life assessment has provided a tool for the comparative analysis of new and conventional antipsychotic medications, particularly regarding their impact on functional status and satisfaction. In a recently concluded study, we demonstrated that the new antipsychotic medications are subjectively much better tolerated and have a more favourable impact on quality of life compared with conventional neuroleptics. The ultimate question is whether such favourable benefits can translate in the future into better compliance with medications and improved long-term outcomes.

International Journal of Social Psychiatry, Vol. 45, No. 4, 268-275 (1999)
DOI: 10.1177/002076409904500405


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Mortimer and A. O. Ahmed Al-Agib Quality Of Life In Schizophrenia On Conventional Versus Atypical Antipsychotic Medication: A Comparative Cross-Sectional Study International Journal of Social Psychiatry, March 1, 2007; 53(2): 99 - 107. [Abstract] [PDF]

				A. H. FRIEDLANDER and S. R. MARDER The psychopathology, medical management and dental implications of schizophrenia J Am Dent Assoc, May 1, 2002; 133(5): 603 - 610. [Abstract] [Full Text] [PDF]

				F. Holloway Special Edition: Quality of Life and Mental Health Services International Journal of Social Psychiatry, December 1, 1999; 45(4): 235 - 237. [PDF]